Literature DB >> 16146534

First-line autologous stem cell transplantation in primary CNS lymphoma.

M Brevet1, R Garidi, B Gruson, B Royer, I Vaida, G Damaj.   

Abstract

The treatment of primary central nervous system lymphoma (PCNSL) has been considerably improved over recent years. In this article, we report six cases of PCNSL treated by first-line induction chemotherapy followed by intensive chemotherapy and autologous stem cell transplantation (ASCT). Six immunocompetent patients presenting with a PCNSL, confirmed by thoraco-abdomino-pelvic computer tomography scan and bone marrow biopsy, were treated with induction chemotherapy followed by BEAM intensive chemotherapy and ASCT and radiotherapy. At the end of the treatment, all the patients were in complete remission. After a median follow-up of 41.5 months (17-70 months), four patients were alive without signs of relapse (median survival: 35.5 months). Two patients died from relapse at 19 and 23 months. The neurotoxicity was low with epilepsy in one patient and persistent left side dysesthesia in another one. These results are fairly encouraging. Other studies with greater numbers of patients and longer follow-up are needed to confirm this study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146534     DOI: 10.1111/j.1600-0609.2005.00508.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

Review 1.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

2.  Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Authors:  Gandhi Damaj; Sarah Ivanoff; Diane Coso; Loïc Ysaebert; Sylvain Choquet; Caroline Houillier; Anne Parcelier; Wajed Abarah; Zora Marjanovic; Rémy Gressin; Reda Garidi; Momar Diouf; Anne-Claire Gac; Jehan Dupuis; Xavier Troussard; Franck Morschhauseur; Hervé Ghesquières; Carole Soussain
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

3.  High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Authors:  E Schorb; C P Fox; K Fritsch; L Isbell; A Neubauer; A Tzalavras; R Witherall; S Choquet; O Kuittinen; D De-Silva; K Cwynarski; C Houillier; K Hoang-Xuan; V Touitou; N Cassoux; J-P Marolleau; J Tamburini; R Houot; V Delwail; G Illerhaus; C Soussain; B Kasenda
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

4.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 5.  Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.

Authors:  Andrés José María Ferreri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

Review 7.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

8.  Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.

Authors:  Gareth Gregory; Ashwini Arumugaswamy; Teresa Leung; Kah-Lok Chan; Melody Abikhair; Constantine Tam; Ashish Bajel; Lawrence Cher; Andrew Grigg; David Ritchie; Stephen Opat
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300

9.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M Deangelis
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

10.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.